Relypsa raises $80 million for hyperkalaemia drug
This article was originally published in Scrip
Relypsa said on 15 August that it closed an $80 million series C preferred stock financing after it disclosed in a US Securities and Exchange Commission (SEC) filing on 10 August that it raised $49.7 million to begin a Phase III trial this year and a future new drug application (NDA) to the US FDA for patiromer (RLY5016), a high-capacity, non-absorbed oral potassium binder to treat hyperkalaemia in patients with diabetes, chronic kidney disease (CKD) and heart failure (scripintelligence.com, 14 August 2012).
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.